Search results
Showing 351 to 400 of 4090 results for patient
This guideline covers diagnosing and managing age-related macular degeneration (AMD) in adults. It aims to improve the speed at which people are diagnosed and treated to prevent loss of sight.
Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)
Evidence-based recommendations on obinutuzumab (Gazyvaro) with chlorambucil for untreated chronic lymphocytic leukaemia in adults.
Evidence-based recommendations on gefitinib (Iressa) for untreated locally advanced or metastatic non-small-cell lung cancer in adults.
This guideline covers helping adults and young people over 16 who are dependent on opioids to stop using drugs. It aims to reduce illicit drug use and improve people’s physical and mental health, relationships and employment.
This quality standard covers diagnosing and managing atopic eczema in children under 12. It describes high-quality care in priority areas for improvement.
View quality statements for QS44Show all sections
Sections for QS44
- Quality statements
- Quality statement 1: Assessment at diagnosis
- Quality statement 2: Stepped approach to management
- Quality statement 3: Psychological wellbeing and quality of life
- Quality statement 4: Provision of emollients
- Quality statement 5: Referral for specialist dermatological advice
- Quality statement 6: Specialist allergy investigation
- Quality statement 7: Treatment of eczema herpeticum
Evidence-based recommendations on colistimethate sodium (Colobreathe) and tobramycin (TOBI Podhaler) dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis in people of 6 years and over.
Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (TA268)
Evidence-based recommendations on ipilimumab (Yervoy) for previously treated advanced melanoma in adults.
Eltrombopag for treating chronic immune thrombocytopenia (TA293)
Evidence-based recommendations on eltrombopag (Revolade) for treating chronic immune thrombocytopenia in adults.
This quality standard covers preventing bacterial infection in newborn babies, treating pregnant women and pregnant people whose babies are at risk of infection, and treating newborn babies with suspected or confirmed bacterial infection. It includes when to give antibiotics to prevent and treat neonatal bacterial infection and describes high-quality care in priority areas for improvement. This includes early-onset (within 72 hours of birth) and late-onset (between 72 hours and 28 days following birth) neonatal infection.
View quality statements for QS75Show all sections
Sections for QS75
- Quality statements
- Quality statement 1: Intrapartum antibiotics
- Quality statement 2: Assessment for early-onset neonatal infection
- Quality statement 3: Prompt antibiotic treatment for neonatal infection
- Quality statement 4: Reassessing antibiotic treatment for neonatal infection
- Quality statement 5: Information and support for parents and carers
- Update information
- About this quality standard
Aflibercept for treating choroidal neovascularisation (TA486)
Evidence-based recommendations on aflibercept (Eylea) for treating choroidal neovascularisation in adults.
This quality standard covers preventing and controlling infection in adults, young people and children receiving healthcare in primary, community and secondary care settings. It includes preventing healthcare-associated infections that develop because of treatment or from being in a healthcare setting. It describes high-quality care in priority areas for improvement.
View quality statements for QS61Show all sections
Sections for QS61
- Quality statements
- Quality statement 1: Antimicrobial stewardship
- Quality statement 2: Organisational responsibility
- Quality statement 3: Hand decontamination
- Quality statement 4: Urinary catheters
- Quality statement 5: Vascular access devices
- Quality statement 6: Educating people about infection prevention and control
- Update information
Infliximab for treating moderate to severe plaque psoriasis (TA134)
Evidence-based recommendations on infliximab for treating moderate to severe psoriasis in adults.
Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)
Evidence-based recommendations on mannitol dry powder for inhalation (Bronchitol) for treating cystic fibrosis in adults
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab (Simponi), tocilizumab (RoActemra) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried conventional DMARDs only but they have not worked.
annuloplasty for mitral valve repair. Studies should include details on patient selection, type and size of valve used, functional...
This guideline covers how to increase uptake of the free flu vaccination among people who are eligible. It describes ways to increase awareness and how to use all opportunities in primary and secondary care to identify people who should be encouraged to have the vaccination.
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer (TA653)
Evidence-based recommendations on osimertinib (Tagrisso) for treating epidermal growth factor receptor (EGFR) T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults.
Evidence-based recommendations on bevacizumab (Avastin), sorafenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for treating advanced or metastatic renal cell carcinoma in adults.
Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for treating advanced (unresectable or metastatic) melanoma in adults.
Teriflunomide for treating relapsing–remitting multiple sclerosis (TA303)
Evidence-based recommendations on teriflunomide (Aubagio) for treating relapsing–remitting multiple sclerosis in adults.
HealOzone for the treatment of tooth decay (occlusal pit and fissure caries and root caries) (TA92)
Evidence-based recommendations on using an ozone-releasing device (HealOzone) in people with tooth decay.
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)
Evidence-based recommendations on bevacizumab (Avastin) and cetuximab (Erbitux) for treating metastatic colorectal cancer in adults.
Roflumilast for treating chronic obstructive pulmonary disease (TA461)
Evidence-based recommendations on roflumilast (Daxas) for treating chronic obstructive pulmonary disease in adults with chronic bronchitis.
Ustekinumab for treating moderate to severe plaque psoriasis (TA180)
Evidence-based recommendations on ustekinumab (Stelara) for treating psoriasis in adults.
Golimumab for treating active non-radiographic axial spondyloarthritis (TA497)
Evidence-based recommendations on golimumab (Simponi) for treating active non-radiographic axial spondyloarthritis.
Evidence-based recommendations on cobimetinib (Cotellic) with vemurafenib (Zelboraf) for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.
Evidence-based recommendations on axitinib (Inlyta) for previously treated advanced renal cell carcinoma in adults.
Evidence-based recommendations on ivacaftor–tezacaftor–elexacaftor (Kaftrio) plus ivacaftor (Kalydeco), tezacaftor–ivacaftor (Symkevi) plus ivacaftor, and lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis.
Everolimus for advanced renal cell carcinoma after previous treatment (TA432)
Evidence-based recommendations on everolimus (Afinitor) for advanced renal cell carcinoma after previous treatment.
Obeticholic acid for treating primary biliary cholangitis (TA443)
Evidence-based recommendations on obeticholic acid (Ocaliva) for treating primary biliary cholangitis in adults.
This quality standard covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It describes high-quality care in priority areas for improvement.
View quality statements for QS208Show all sections
Sections for QS208
- Quality statements
- Quality statement 1: Structured education programmes
- Quality statement 2: Continuous glucose monitoring
- Quality statement 3: Statin therapy for primary prevention of cardiovascular disease
- Quality statement 4: 9 key care processes
- Quality statement 5: Assessing the risk of diabetic foot problems on admission to hospital
- Quality statement 6: Support to self-manage diabetes during inpatient admissions
- Quality statement 7 (placeholder): Identification of eating disorders in adults with type 1 diabetes
This guideline covers the recognition, diagnosis and early management of suspected sepsis in pregnant or recently pregnant people. It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.
This quality standard covers managing urinary incontinence in women (aged 18 and over). It covers assessment, care and treatment options. It describes high-quality care in priority areas for improvement.
View quality statements for QS77Show all sections
Sections for QS77
- Quality statements
- Quality statement 1: Initial assessment
- Quality statement 2: Bladder diaries and lifestyle changes
- Quality statement 3: Containment products
- Quality statement 4: Supervised pelvic floor muscle training
- Quality statement 5: Bladder training
- Quality statement 6: Indwelling catheters
- Quality statement 7: Multidisciplinary team review before surgery or invasive treatment
Evidence-based recommendations on abiraterone (Zytiga) for castration-resistant metastatic prostate cancer in adults who have had previous treatment with a docetaxel-containing regimen.
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer (TA227)
Evidence-based recommendations on erlotinib (Tarceva) for the maintenance treatment of non-small-cell lung cancer in adults.
Endobronchial ultrasound-guided transbronchial biopsy for peripheral lung lesions (HTG214)
Evidence-based recommendations on endobronchial ultrasound-guided transbronchial biopsy for peripheral lung lesions. This involves inserting an ultrasound probe via the patient’s nose or mouth into the lungs to obtain images as a guide for taking samples of the lesions.
View recommendations for HTG214Show all sections
Sections for HTG214
Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and high-dose imatinib (Glivec) for treating imatinib-resistant or intolerant chronic myeloid leukaemia in adults.
Omalizumab for treating severe persistent allergic asthma (TA278)
Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma in people aged 6 and over.
Developmental follow-up of children and young people born preterm (QS169)
This quality standard covers the developmental follow-up of babies, children and young people under 18 years who were born preterm (before 37+0 weeks of pregnancy). It describes high-quality care in priority areas for improvement.
Evidence-based recommendations on golimumab (Simponi) for treating rheumatoid arthritis in adults.
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events, such as heart attack and stroke, after acute coronary syndrome in adults.
Evidence-based recommendations on bevacizumab (Avastin), with paclitaxel and carboplatin, for treating advanced ovarian cancer in adults.
implanted mitral valve bioprosthesis. Studies should include details on patient selection, type and size of valve used, functional...
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)
Evidence-based recommendations on trametinib (Mekinist) with dabrafenib (Tafinlar) for adults with unresectable or metastatic melanoma that has a BRAF V600 mutation.
Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (TA427)
Evidence-based recommendations on pomalidomide (Imnovid) for multiple myeloma previously treated with lenalidomide and bortezomib in adults.
Darvadstrocel for treating complex perianal fistulas in Crohn's disease (TA556)
Evidence-based recommendations on darvadstrocel (Alofisel) for previously treated complex perianal fistulas in adults with non-active or mildly active luminal Crohn’s disease.
therapy in reducing CVD that can be obtained when using a complete individual patient-based outcomes meta-analysis data set compared...
Evidence-based recommendations on crizotinib (Xalkori) for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.
Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)
Evidence-based recommendations on adalimumab (Humira) and dexamethasone (Ozurdex) for treating non-infectious uveitis in adults.
Acute kidney injury: prevention, detection and management (NG148)
This guideline covers preventing, detecting and managing acute kidney injury in children, young people and adults. It aims to improve assessment and detection by non-specialists, and specifies when people should be referred to specialist services. This will improve early recognition and treatment, and reduce the risk of complications in people with acute kidney injury.